Development of an early detection program for individuals with a family history of Autosomal Dominant Polycystic Kidney Disease
DOI:
https://doi.org/10.56294/sctconf20231113Keywords:
Dialysis, Chronic Kidney Disease, CystsAbstract
Autosomal dominant polycystic kidney disease is an inherited disorder characterized by the development of clusters of fluid-filled sacs primarily in the kidneys, causing enlargement of the organs and possible impairment of their normal functions. This study aims to develop an early detection program for individuals with a family history of Autosomal Dominant Polycystic Kidney Disease based on the underlying pathophysiology and the various diagnostic approaches of Autosomal Dominant Polycystic Kidney Disease to facilitate efficient management and treatment of the disease. condition. The findings clarify the complex nature of this clinical scenario and highlight the significant obstacles that medical professionals encounter in establishing a conclusive diagnosis, thus shedding light on this healthcare dilemma within the scientific community. The pathophysiology of the disease has been determined to be closely related to genetic mutations in the PKD1 and PKD2 genes, which ultimately leads to structural and functional deterioration of the kidneys; in particular, the use of ultrasound images, which incorporate established criteria in the diagnostic process.
References
1. Zahir ST, Asl ZS, Firoozi R, et al. Polycystic kidney disease and cognitive function: a cross-sectional study in Iranian patients. Clin Exp Nephrol. 2021;25(4):345-353.
2. Müller RU, Benzing T. Management of autosomal-dominant polycystic kidney disease-state-of-the-art. Clin Kidney J. 2021;14(1):110-123.
3. Lanktree MB, Haghighi A, Di Bari I, et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. J Am Soc Nephrol. 2021;32(10):2345-2359.
4. Hwang YH, Conklin J, Chan W, et al. Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2021;32(8):1830-1843.
5. Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol. 2022;33(3):516-528.
6. Ong AC, Devuyst O, Knebelmann B, et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2022;400(10357):1001-1013.
7. Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2022;33(4):817-832.
8. Irazabal MV, Abebe KZ, Bae KT, et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease. Kidney Int Rep. 2021;6(7):1958-1971.
9. Chapman AB, Bost JE, Torres VE, et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol. 2022;17(1):72-82.
10. Guay-Woodford LM. Autosomal dominant polycystic kidney disease: the last 3 years. Clin J Am Soc Nephrol. 2021;16(5):790-799. DOI: https://doi.org/10.2215/CJN.02320220
11. Eisenberger T, Decker C, Hiersche M, et al. An efficient and comprehensive strategy for genetic diagnostics of polycystic kidney disease. PLoS One. 2022;17(2):e0263860.
12. Sweeney WE Jr, Frost P, Avner ED. Current pharmacologic approaches in renal cystic disease: ADPKD and ARPKD. Pediatr Nephrol. 2021;36(5):1113-1128.
13. Chebib FT, Jung YL, Heyer CM, et al. Imaging classification of polycystic kidney disease: the value of 3D ultrasound. Kidney Int Rep. 2021;6(6):1585-1595.
14. Kim H, Park HC, Ryu H, et al. Genetic analysis of ADPKD patients using next-generation sequencing. Ann Lab Med. 2021;41(2):186-193.
15. Warner G, Hein KZ, Nin V, et al. Validation of an imaging-based prediction tool in a pre-dialysis cohort with autosomal dominant polycystic kidney disease. BMC Nephrol. 2021;22(1):234.
16. Harris PC, Torres VE. Genetic mechanisms and signaling pathways in ADPKD. J Clin Invest. 2022;132(4):e148382.
17. Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant. 2021;36 (9):2395-2405.
18. Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2021;17(9):563-573.
19. Devuyst O, Torres VE. Polycystic kidney disease: new concepts and challenges. Lancet. 2021;398(10209):2511-2525.
20. Messchendorp AL, Meijer E, Torres VE, et al. Tesevatinib in patients with autosomal dominant polycystic kidney disease: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet Kidney Dis. 2022;4(3):183-192.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Alex Ramón Valencia Herrera, Liliana Katherine Sailema López, Génesis Alexandra Zúñiga Cárdenas, Aldemar Alejandro Monsalve Guamán (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
